The technology has been developed to treat patients with aortic valvular disease. Credit: Natali _ Mis / Shutterstock.com.

Genesis MedTech has secured breakthrough device designation from the US Food and Drug Administration (FDA) for its J-Valve Transfemoral (TF) System.

The company has developed the technology to treat patients with aortic valvular disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The device has received breakthrough status for its use in treating severe native aortic regurgitation (AR) and aortic valve disease characterised by dominant AR in patients.

It comprises the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device components.

The bioprosthesis includes bovine pericardium leaflets, a nitinol anchor ring and a nitinol stent frame covered with polyester fabric.

See Also:

The delivery device helps place the bioprosthesis within the native aortic valve.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A minimally invasive transvascular approach helps carry out the J-Valve transcatheter aortic valve replacement procedure.

The device deploys an anchor mechanism and an expanding stent frame to attach to a failing valve.

It can potentially alleviate heart failure symptoms such as chest pain, fatigue and breathing trouble by aiding in the restoration of normal blood flow from the heart to the body.

Genesis MedTech Group chairman and CEO Warren Wang said: “We believe the Breakthrough Device designation for the J-Valve TF System is a testament to the innovative spirit and dedication of our team at Genesis MedTech.

“We are committed to developing cutting-edge medical devices that address unmet clinical needs and improve patient outcomes and this designation is a significant milestone in that journey.”